Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Human Immunology|May 16, 2006
Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patientsHelmut Rainer Salih, Dennis Goehlsdorf, Alexander SteinleFrontiers in Bioscience : a Journal and Virtual Library|May 30, 2008
Soluble NKG2D ligands: prevalence, release, and functional impactHelmut Rainer Salih, Stefan Holdenrieder, Alexander SteinleClinical & Developmental Immunology|October 12, 2010
Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulationTheresa Placke, Hans-Georg Kopp, Helmut Rainer SalihCancer Research|September 10, 2009
Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivityHans-Georg Kopp, Theresa Placke, Helmut Rainer SalihJournal of Innate Immunity|March 18, 2011
Modulation of natural killer cell anti-tumor reactivity by plateletsTheresa Placke, Hans-Georg Kopp, Helmut Rainer SalihOncoimmunology|July 4, 2012
The wolf in sheep's clothing: Platelet-derived "pseudo self" impairs cancer cell "missing self" recognition by NK cellsTheresa Placke, Hans-Georg Kopp, Helmut Rainer SalihOncoimmunology|June 14, 2013
A "vicious cycle" of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?Benjamin Joachim Schmiedel, Ludger Grosse-Hovest, Helmut Rainer SalihCancer Immunology, Immunotherapy : CII|April 26, 2006
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICAStefan Holdenrieder, Petra Stieber, Andrea Peterfi, et al.International Journal of Cancer|August 12, 2005
Soluble MICA in malignant diseasesStefan Holdenrieder, Petra Stieber, Andrea Peterfi, et al.International Journal of Cancer|February 10, 2010
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivityJulia Salih, Julia Hilpert, Theresa Placke, et al.Pageof 4